HN1999000196A - Derivados de indol - Google Patents

Derivados de indol

Info

Publication number
HN1999000196A
HN1999000196A HN1999000196A HN1999000196A HN1999000196A HN 1999000196 A HN1999000196 A HN 1999000196A HN 1999000196 A HN1999000196 A HN 1999000196A HN 1999000196 A HN1999000196 A HN 1999000196A HN 1999000196 A HN1999000196 A HN 1999000196A
Authority
HN
Honduras
Prior art keywords
indol derivatives
indol
derivatives
bromhydrate
procedure
Prior art date
Application number
HN1999000196A
Other languages
English (en)
Inventor
Ian Dallman Cristopher
James Ogilvie Ronald
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HN1999000196A publication Critical patent/HN1999000196A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Lasers (AREA)
  • Electroluminescent Light Sources (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A DERIVADOS DEL INDOL MAS ESPECIALMENTE, LA PRESENTE INVENCION SE REFIERE A BROMHIDRATO DE ELECTRIPTAN MONOHIDRATADO, A PROCEDIMIENTO PARA SU PREPARACION, A PROCEDIMIENTO PARA SU CONVERSION EN BROMHIDRATO DE ELECTRIPTAN ANHIDRO Y A LOS USOS DE DICHO MONOHIDRATO, Y A COMPOSICIONES QUE LO CONTIENEN.
HN1999000196A 1998-11-27 1999-11-09 Derivados de indol HN1999000196A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9825988.0A GB9825988D0 (en) 1998-11-27 1998-11-27 Indole derivatives

Publications (1)

Publication Number Publication Date
HN1999000196A true HN1999000196A (es) 2005-11-26

Family

ID=10843140

Family Applications (1)

Application Number Title Priority Date Filing Date
HN1999000196A HN1999000196A (es) 1998-11-27 1999-11-09 Derivados de indol

Country Status (53)

Country Link
US (2) US20020013358A1 (es)
EP (1) EP1135381B1 (es)
JP (1) JP3777094B2 (es)
KR (1) KR100413739B1 (es)
CN (1) CN1131860C (es)
AP (1) AP2001002149A0 (es)
AR (1) AR024232A1 (es)
AT (1) ATE273300T1 (es)
AU (1) AU754731B2 (es)
BG (1) BG64706B1 (es)
BR (1) BR9915692A (es)
CA (1) CA2352392C (es)
CO (1) CO5150178A1 (es)
CR (1) CR6325A (es)
CU (1) CU23269A3 (es)
CZ (1) CZ295472B6 (es)
DE (1) DE69919388T2 (es)
DK (1) DK1135381T3 (es)
DZ (1) DZ2948A1 (es)
EA (1) EA003551B1 (es)
EE (1) EE04914B1 (es)
ES (1) ES2224701T3 (es)
GB (1) GB9825988D0 (es)
GC (1) GC0000113A (es)
GE (1) GEP20043183B (es)
GT (1) GT199900202A (es)
HK (1) HK1042898B (es)
HN (1) HN1999000196A (es)
HR (1) HRP20010398B1 (es)
HU (1) HUP0105308A3 (es)
ID (1) ID28802A (es)
IL (1) IL141663A (es)
IS (1) IS2238B (es)
MA (1) MA26708A1 (es)
MY (1) MY124078A (es)
NO (1) NO320798B1 (es)
NZ (1) NZ510055A (es)
OA (1) OA11671A (es)
PA (1) PA8485701A1 (es)
PE (1) PE20001299A1 (es)
PL (1) PL194503B1 (es)
PT (1) PT1135381E (es)
RS (1) RS50002B (es)
SI (1) SI1135381T1 (es)
SK (1) SK285774B6 (es)
SV (1) SV1999000204A (es)
TN (1) TNSN99221A1 (es)
TR (1) TR200101493T2 (es)
TW (1) TWI246512B (es)
UA (1) UA68402C2 (es)
UY (2) UY25823A1 (es)
WO (1) WO2000032589A1 (es)
ZA (1) ZA200102681B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
JP2006522790A (ja) 2003-04-11 2006-10-05 ファイザー・インク エレトリプタンと重炭酸ナトリウムを含む医薬組み合わせ物
GB0317229D0 (en) * 2003-07-23 2003-08-27 Pfizer Ltd Improved process
US6927296B2 (en) 2003-07-23 2005-08-09 Pfizer Inc. Process
EP2046777A2 (en) 2007-05-01 2009-04-15 Plus Chemicals B.V. Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide
EP2038273A1 (en) * 2007-05-29 2009-03-25 Plus Chemicals B.V. A process for preparing 5-bromo-3-[(r)-1-methyl-pyrrolidin-2-ylmethyl]-1h-indole
EP2225224A2 (en) * 2007-12-17 2010-09-08 Actavis Group PTC EHF Novel hemioxalate salt of eletriptan
US20120027816A1 (en) * 2009-02-25 2012-02-02 Actavis Group Ptc Ehf Highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan n-oxide impurity
WO2010116386A2 (en) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
US8754239B2 (en) 2010-01-19 2014-06-17 Sms Pharmaceuticals Limited Process for preparing eletriptan hydrobromide having α-form
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
CN103893112A (zh) * 2012-12-31 2014-07-02 重庆圣华曦药业股份有限公司 氢溴酸依来曲普坦注射液
CN107954947A (zh) * 2016-10-14 2018-04-24 北京莱瑞森医药科技有限公司 沃替西汀氢溴酸盐晶型c及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952741A (en) * 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
US5474784A (en) * 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
HUT64326A (en) 1990-10-15 1993-12-28 Pfizer Process for production indole derivatives and pharmaceutical preparations containing these compounds
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9510223D0 (en) * 1995-05-20 1995-07-19 Pfizer Ltd Therapeutic agent
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
US5998462A (en) * 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) * 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
NZ501419A (en) 1997-07-03 2000-09-29 Pfizer Pharmaceutical compositions containing eletriptan hemisulphate and caffeine for treating migraines, depression and eating disorders

Also Published As

Publication number Publication date
US7238723B2 (en) 2007-07-03
CA2352392A1 (en) 2000-06-08
EA003551B1 (ru) 2003-06-26
SK285774B6 (sk) 2007-08-02
UY25823A1 (es) 2001-08-27
KR20010080594A (ko) 2001-08-22
PA8485701A1 (es) 2000-09-29
ES2224701T3 (es) 2005-03-01
AP2001002149A0 (en) 2001-06-30
TWI246512B (en) 2006-01-01
DZ2948A1 (fr) 2004-03-15
EP1135381A1 (en) 2001-09-26
BG105539A (en) 2001-12-29
GT199900202A (es) 2001-05-19
AU754731B2 (en) 2002-11-21
DE69919388D1 (de) 2004-09-16
HRP20010398A2 (en) 2002-06-30
ID28802A (id) 2001-07-05
EE200100285A (et) 2002-08-15
IL141663A0 (en) 2002-03-10
SI1135381T1 (en) 2004-10-31
TNSN99221A1 (fr) 2005-11-10
JP3777094B2 (ja) 2006-05-24
AU6225399A (en) 2000-06-19
RS50002B (sr) 2008-09-29
NZ510055A (en) 2004-11-26
EA200100297A1 (ru) 2001-08-27
US20050131237A1 (en) 2005-06-16
NO320798B1 (no) 2006-01-30
MY124078A (en) 2006-06-30
CZ20011839A3 (cs) 2001-10-17
TR200101493T2 (tr) 2002-02-21
CA2352392C (en) 2006-01-24
PE20001299A1 (es) 2000-12-01
SV1999000204A (es) 2000-10-16
DK1135381T3 (da) 2004-11-15
IL141663A (en) 2004-05-12
GEP20043183B (en) 2004-02-25
PL347928A1 (en) 2002-04-22
UA68402C2 (en) 2004-08-16
YU18801A (sh) 2003-07-07
CR6325A (es) 2008-07-02
HRP20010398B1 (en) 2004-12-31
CN1328554A (zh) 2001-12-26
KR100413739B1 (ko) 2004-01-03
IS5868A (is) 2001-02-27
CN1131860C (zh) 2003-12-24
GB9825988D0 (en) 1999-01-20
HUP0105308A3 (en) 2003-01-28
NO20012584D0 (no) 2001-05-25
JP2002531449A (ja) 2002-09-24
HK1042898A1 (en) 2002-08-30
DE69919388T2 (de) 2005-09-29
ZA200102681B (en) 2002-07-02
HUP0105308A2 (hu) 2002-05-29
NO20012584L (no) 2001-07-27
CO5150178A1 (es) 2002-04-29
BR9915692A (pt) 2001-08-14
EP1135381B1 (en) 2004-08-11
GC0000113A (en) 2005-06-29
UY25825A1 (es) 2000-08-21
BG64706B1 (bg) 2005-12-30
CU23269A3 (es) 2008-04-09
IS2238B (is) 2007-05-15
OA11671A (en) 2005-01-12
PL194503B1 (pl) 2007-06-29
SK6992001A3 (en) 2002-01-07
WO2000032589A1 (en) 2000-06-08
CZ295472B6 (cs) 2005-08-17
EE04914B1 (et) 2007-10-15
US20020013358A1 (en) 2002-01-31
HK1042898B (zh) 2004-10-08
MA26708A1 (fr) 2004-12-20
PT1135381E (pt) 2004-10-29
ATE273300T1 (de) 2004-08-15
AR024232A1 (es) 2002-09-25

Similar Documents

Publication Publication Date Title
GT199900102A (es) Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen.
HN2001000027A (es) Derivados de purina
GT199900215A (es) Formulaciones agroquimicas.
HN1999000106A (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
HN1999000196A (es) Derivados de indol
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
UY27098A1 (es) Derivados de indol
HN2001000224A (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
SV2001000004A (es) Difenil ureas w-carboxyaril sustituidas, composición farmacéutica que las comprende y su uso como inhibidores de raf quinasa
SV1997000009A (es) Nuevas oxazolidinonas sustituidas ref. lea 31534-sv
PA8521001A1 (es) Derivados de purina
DE60106954D1 (de) Resorcin-derivate
PA8654701A1 (es) Indoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
HN2002000300A (es) Nuevos derivados de piperazina
MX9202152A (es) Derivados del indol, procedimiento para su preparacion y composicion farmaceutica que los contiene.
ES2187738T3 (es) Derivados de flavonas, su procedimiento de preparacion y los compuestos farmaceuticos que las contienen.
HN2001000235A (es) Derivados puentes de piperazina
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
PA8469101A1 (es) Ligandos azabiciclicos de receptores 5ht1
ES2186989T3 (es) Cristales de maltitol de formas especificas, compuestos cristalinos que los contienen y procedimientos para su preparacion.
CO4600682A1 (es) Protrombinas como antidoto para los inhibidores de la trom- bina
HN1999000101A (es) Inhibidores de las fkbp.
AR034451A1 (es) Microcapsulas para la proteccion frente al mal aliento.
ES2174297T3 (es) Nuevos derivados de piranosidos.